Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 in relapsed/refractory diffuse large B-cell lymphoma
2023-508508-39-01Phase 2Completed
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) and 3 more, sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Objective response rate. Started Jun 2024; status: completed.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)transformed lymphomaprimary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2023-508508-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508508-39-01.